<mods xmlns="http://www.loc.gov/mods/v3" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xsi:schemaLocation="http://www.loc.gov/mods/v3 http://www.loc.gov/standards/mods/v3/mods-3-3.xsd" version="3.3" ID="P0b002ee18b4865dc">
<name type="corporate">
 <namePart>United States Government Publishing Office</namePart>
 <role>
  <roleTerm type="text" authority="marcrelator">publisher</roleTerm>
  <roleTerm type="code" authority="marcrelator">pbl</roleTerm>
</role>
 <role>
  <roleTerm type="text" authority="marcrelator">distributor</roleTerm>
  <roleTerm type="code" authority="marcrelator">dst</roleTerm>
</role>
</name>
<name type="corporate">
 <namePart>United States</namePart>
 <namePart>Congress</namePart>
 <namePart>House of Representatives</namePart>
 <role>
  <roleTerm type="text" authority="marcrelator">author</roleTerm>
  <roleTerm type="code" authority="marcrelator">aut</roleTerm>
</role>
 <description>Government Organization</description>
</name>
<typeOfResource>text</typeOfResource>
<genre authority="marcgt">government publication</genre>
<language>
 <languageTerm authority="iso639-2b" type="code">eng</languageTerm>
</language>
<extension>
 <collectionCode>BILLS</collectionCode>
 <searchTitle>To amend the Federal Food, Drug, and Cosmetic Act to authorize a 6-month extension of certain exclusivity periods in the case of approved drugs that are subsequently approved for a new indication to prevent, diagnose, or treat a rare disease or condition, and for other purposes.;Orphan Product Extensions Now Accelerating Cures and Treatments Act of 2015;H.R. 971 (IH)</searchTitle>
 <category>Bills and Statutes</category>
 <waisDatabaseName>114_cong_bills</waisDatabaseName>
 <branch>legislative</branch>
 <dateIngested>2015-02-26</dateIngested>
</extension>
<titleInfo>
 <title>To amend the Federal Food, Drug, and Cosmetic Act to authorize a 6-month extension of certain exclusivity periods in the case of approved drugs that are subsequently approved for a new indication to prevent, diagnose, or treat a rare disease or condition, and for other purposes.</title>
</titleInfo>
<titleInfo type="alternative">
 <title>Orphan Product Extensions Now Accelerating Cures and Treatments Act of 2015</title>
</titleInfo>
<titleInfo type="alternative">
 <title>H.R. 971 (IH)</title>
</titleInfo>
<originInfo>
 <publisher>U.S. Government Publishing Office</publisher>
 <dateIssued encoding="w3cdtf">2015-02-13</dateIssued>
 <issuance>monographic</issuance>
</originInfo>
<physicalDescription>
 <note type="source content type">deposited</note>
 <digitalOrigin>born digital</digitalOrigin>
 <extent>11 p.</extent>
</physicalDescription>
<classification authority="sudocs">Y 1.6:</classification>
<classification authority="sudocs">Y 1.4/6:</classification>
<identifier type="local">P0b002ee18b4865dc</identifier>
<identifier type="uri">https://www.gpo.gov/fdsys/pkg/BILLS-114hr971ih</identifier>
<identifier type="preferred citation">H.R. 971</identifier>
<identifier type="stock number">021-610-00252-9</identifier>
<identifier type="Parent ILS system id">000501532</identifier>
<identifier type="Child ILS system id">000325573</identifier>
<identifier type="Parent ILS title">Congressional bills</identifier>
<identifier type="Child ILS title">House bills</identifier>
<identifier type="former package identifier">f:h971_ih.txt</identifier>
<location xmlns:exslt="http://exslt.org/common">
 <url access="object in context" displayLabel="Content Detail">https://www.gpo.gov/fdsys/pkg/BILLS-114hr971ih/content-detail.html</url>
 <url access="raw object" displayLabel="HTML rendition">https://www.gpo.gov/fdsys/pkg/BILLS-114hr971ih/html/BILLS-114hr971ih.htm</url>
 <url access="raw object" displayLabel="PDF rendition">https://www.gpo.gov/fdsys/pkg/BILLS-114hr971ih/pdf/BILLS-114hr971ih.pdf</url>
 <url access="raw object" displayLabel="XML rendition">https://www.gpo.gov/fdsys/pkg/BILLS-114hr971ih/xml/BILLS-114hr971ih.xml</url>
</location>
<accessCondition type="GPO scope determination">fdlp</accessCondition>
<recordInfo>
 <recordContentSource authority="marcorg">DGPO</recordContentSource>
 <recordCreationDate encoding="w3cdtf">2015-02-26</recordCreationDate>
 <recordChangeDate encoding="w3cdtf">2016-10-13</recordChangeDate>
 <recordIdentifier source="DGPO">BILLS-114hr971ih</recordIdentifier>
 <recordOrigin>machine generated</recordOrigin>
 <languageOfCataloging>
  <languageTerm authority="iso639-2b" type="code">eng</languageTerm>
</languageOfCataloging>
</recordInfo>
<name type="personal">
 <namePart>Gus M. Bilirakis</namePart>
 <affiliation>United States House of Representatives</affiliation>
 <role>
  <roleTerm type="text" authority="marcrelator">sponsor</roleTerm>
  <roleTerm type="code" authority="marcrelator">spn</roleTerm>
</role>
 <description>United States Congress Member</description>
</name>
<name type="personal">
 <namePart>Michael T. McCaul</namePart>
 <affiliation>United States House of Representatives</affiliation>
 <role>
  <roleTerm type="text">cosponsor</roleTerm>
</role>
 <description>United States Congress Member</description>
</name>
<name type="personal">
 <namePart>G. K. Butterfield</namePart>
 <affiliation>United States House of Representatives</affiliation>
 <role>
  <roleTerm type="text">cosponsor</roleTerm>
</role>
 <description>United States Congress Member</description>
</name>
<name type="corporate">
 <namePart>United States</namePart>
 <namePart>Congress</namePart>
 <namePart>House of Representatives</namePart>
 <namePart>Committee on Energy and Commerce</namePart>
 <role>
  <roleTerm type="text" authority="marcrelator">associated name</roleTerm>
  <roleTerm type="code" authority="marcrelator">asn</roleTerm>
</role>
</name>
<relatedItem xmlns:exslt="http://exslt.org/common" type="isReferencedBy">
 <titleInfo>
  <title>United States Code</title>
  <partNumber>Title 21 Section 355a</partNumber>
  <partNumber>Title 21 Section 355(c)</partNumber>
  <partNumber>Title 21 Section 355f</partNumber>
</titleInfo>
 <identifier type="USC citation">21 U.S.C. 355a</identifier>
 <identifier type="USC citation">21 U.S.C. 355(c)</identifier>
 <identifier type="USC citation">21 U.S.C. 355f</identifier>
</relatedItem>
<relatedItem xmlns:exslt="http://exslt.org/common" type="isReferencedBy">
 <titleInfo>
  <title>United States Code</title>
  <partNumber>Title 42 Section 262(a)</partNumber>
  <partNumber>Title 42 Section 262(m)</partNumber>
</titleInfo>
 <identifier type="USC citation">42 U.S.C. 262(a)</identifier>
 <identifier type="USC citation">42 U.S.C. 262(m)</identifier>
</relatedItem>
<extension>
 <docClass>hr</docClass>
 <accessId>BILLS-114hr971ih</accessId>
 <congress>114</congress>
 <session>1</session>
 <originChamber>HOUSE</originChamber>
 <currentChamber>HOUSE</currentChamber>
 <billNumber>971</billNumber>
 <billVersion reprint="false">ih</billVersion>
 <fileSuffix>ih</fileSuffix>
 <shortTitle type="measure">Orphan Product Extensions Now Accelerating Cures and Treatments Act of 2015</shortTitle>
 <officialTitle>To amend the Federal Food, Drug, and Cosmetic Act to authorize a 6-month extension of certain exclusivity periods in the case of approved drugs that are subsequently approved for a new indication to prevent, diagnose, or treat a rare disease or condition, and for other purposes.</officialTitle>
 <action date="2015-02-13">Mr. Bilirakis (for himself, Mr. McCaul, and Mr. Butterfield) introduced the following bill; which was referred to the Committee on Energy and Commerce</action>
 <congCommittee authorityId="hsif00" chamber="H" congress="114" type="S">
                      <name type="authority-standard">Committee on Energy and Commerce</name>
                      <name type="authority-short">Energy and Commerce</name>
                </congCommittee>
 <congMember authorityId="1838" bioGuideId="B001257" chamber="H" congress="114" gpoId="7881" party="R" role="SPONSOR" state="FL">
                      <name type="parsed">Mr. Bilirakis</name>
                      <name type="authority-fnf">Gus M. Bilirakis</name>
                      <name type="authority-lnf">Bilirakis, Gus M.</name>
                      <name type="authority-other">Mr. Gus Bilirakis</name>
                </congMember>
 <congMember authorityId="1804" bioGuideId="M001157" chamber="H" congress="114" gpoId="8166" party="R" role="COSPONSOR" state="TX">
                      <name type="parsed">Mr. McCaul</name>
                      <name type="authority-fnf">Michael T. McCaul</name>
                      <name type="authority-lnf">McCaul, Michael T.</name>
                      <name type="authority-other">Mr. Michael Mccaul</name>
                </congMember>
 <congMember authorityId="1761" bioGuideId="B001251" chamber="H" congress="114" gpoId="8024" party="D" role="COSPONSOR" state="NC">
                      <name type="parsed">Mr. Butterfield</name>
                      <name type="authority-fnf">G. K. Butterfield</name>
                      <name type="authority-lnf">Butterfield, G. K.</name>
                </congMember>
 <isPrivate>false</isPrivate>
 <isAppropriation>false</isAppropriation>
 <USCode title="21">
                      <section number="355a"></section>
                      <section detail="(c)" number="355"></section>
                      <section number="355f"></section>
                </USCode>
 <USCode title="42">
                      <section detail="(a)" number="262"></section>
                      <section detail="(m)" number="262"></section>
                </USCode>
</extension>
</mods>